Valuation: Genovis AB

Market Cap 1.32B 137M 120M 111M 102M 192M 13.2B 196M 520M 6.47B 515M 504M 22.26B P/E 2026 *
51.3x
P/E 2027 * 31.7x
Enterprise Value 1.21B 125M 109M 101M 93.05M 175M 12.06B 179M 475M 5.9B 470M 460M 20.33B EV / Sales 2026 *
8.07x
EV / Sales 2027 * 6.15x
Free-Float
94.56%
Yield 2026 *
-
Yield 2027 * -
1 day+5.71%
1 week+5.37%
Current month+1.52%
1 month+9.17%
3 months-0.50%
6 months-7.83%
Current year-5.88%
1 week 18.4
Extreme 18.4
20.2
1 month 17.88
Extreme 17.88
21.2
Current year 15.64
Extreme 15.64
23.65
1 year 15.64
Extreme 15.64
29
3 years 15.64
Extreme 15.64
57.6
5 years 15.64
Extreme 15.64
90
10 years 1.66
Extreme 1.66
90
Manager TitleAgeSince
Chief Executive Officer 55 2015-05-04
Director of Finance/CFO 55 2021-12-31
Chief Tech/Sci/R&D Officer 42 2016-12-31
Director TitleAgeSince
Chairman 74 2020-05-04
Director/Board Member 65 2018-12-31
Director/Board Member 77 2013-12-31
Date Insider Type Main position Quantity % Market Cap.
5/15/26 Buy 4,146 0.0063%
2/24/26 Buy

Chief Financial Officer

2,470 0.0037%
2/24/26 Buy

Chief Financial Officer

3,137 0.0047%
Change 5-day change 1-year change 3-year change Capi.($)
+5.71%+5.37%-28.19%-54.70% 137M
+0.56%-2.61%+235.49%+311.48% 20.67B
+0.41%+4.58%-38.34%-21.74% 9.85B
+2.36%+1.85%+53.31%+18.55% 7B
-1.66%+2.36%+260.00%-25.12% 5.55B
+0.36%+3.63%-17.20%-24.16% 5.23B
+10.00%+34.69%+101.94%+130.90% 4.9B
+0.06%-2.94%-45.38% - 4.66B
-0.66%+0.73%-23.40%-26.29% 4.2B
-2.66%+4.71%-15.83%-39.64% 2.72B
Average +1.45%+5.78%+48.24%+29.92% 6.49B
Weighted average by Cap. +1.00%+3.67%+97.94%+107.90%

Financials

2026 *2027 *
Net sales 150M 15.52M 13.56M 12.52M 11.54M 21.74M 1.49B 22.23M 58.84M 732M 58.29M 57.01M 2.52B 189M 19.62M 17.15M 15.82M 14.58M 27.49M 1.89B 28.1M 74.38M 925M 73.68M 72.06M 3.19B
Net income 22.15M 2.3M 2.01M 1.85M 1.71M 3.22M 221M 3.29M 8.71M 108M 8.63M 8.44M 373M 39.75M 4.12M 3.6M 3.33M 3.07M 5.78M 397M 5.91M 15.63M 195M 15.49M 15.15M 670M
Net Debt -115M -11.89M -10.39M -9.59M -8.84M -16.66M -1.15B -17.03M -45.09M -561M -44.67M -43.69M -1.93B -158M -16.39M -14.33M -13.22M -12.18M -22.97M -1.58B -23.48M -62.15M -773M -61.56M -60.21M -2.66B
Logo Genovis AB
Genovis AB is a Sweden-based company engaged in the research and development, production and marketing of technologies and products for cellular research. The Company offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The Company markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.
Employees
36
Date Price Change Volume
26-07-17 SEK 20.00 +5.71% 23,175
26-07-16 SEK 18.92 -1.05% 31,476
26-07-15 SEK 19.12 -1.34% 22,039
26-07-14 SEK 19.38 +0.83% 104,029
26-07-13 SEK 19.22 +1.26% 27,794
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
20.00SEK
Average target price
33.00SEK
Spread / Average Target
+65.00%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GENO Stock